Literature DB >> 27647820

Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration.

Madeleine J Swortwood1, Matthew N Newmeyer1,2, Maria Andersson1, Osama A Abulseoud1, Karl B Scheidweiler1, Marilyn A Huestis1,3.   

Abstract

Oral fluid (OF) is an important matrix for monitoring drugs. Smoking cannabis is common, but vaporization and edible consumption also are popular. OF pharmacokinetics are available for controlled smoked cannabis, but few data exist for vaporized and oral routes. Frequent and occasional cannabis smokers were recruited as participants for four dosing sessions including one active (6.9% Δ9 -tetrahydrocannabinol, THC) or placebo cannabis-containing brownie, followed by one active or placebo cigarette, or one active or placebo vaporized cannabis dose. Only one active dose was administered per session. OF was collected before and up to 54 (occasional) or 72 (frequent) h after dosing from cannabis smokers. THC, 11-hydroxy-THC (11-OH-THC), 11-nor-9-carboxy-THC (THCCOOH), tetrahydrocannabivarin (THCV), cannabidiol (CBD), and cannabigerol (CBG) were quantified by liquid chromatography-tandem mass spectrometry. OF cannabinoid Cmax occurred during or immediately after cannabis consumption due to oral mucosa contamination. Significantly greater THC Cmax and significantly later THCV, CBD, and CBG tlast were observed after smoked and vaporized cannabis compared to oral cannabis in frequent smokers only. No significant differences in THC, 11-OH-THC, THCV, CBD, or CBG tmax between routes were observed for either group. For occasional smokers, more 11-OH-THC and THCCOOH-positive specimens were observed after oral dosing than after inhaled routes, increasing % positive cannabinoid results and widening metabolite detection windows after oral cannabis consumption. Utilizing 0.3 µg/L THCV and CBG cut-offs resulted in detection windows indicative of recent cannabis intake. OF pharmacokinetics after high potency CBD cannabis are not yet available precluding its use currently as a marker of recent use. Published 2016. This article is a U.S. Government work and is in the public domain in the USA. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  cannabinoids; edibles; oral fluid; smoking; vaporizer

Mesh:

Substances:

Year:  2016        PMID: 27647820      PMCID: PMC5357602          DOI: 10.1002/dta.2092

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  33 in total

1.  Detection of drugs of abuse in simultaneously collected oral fluid, urine and blood from Norwegian drug drivers.

Authors:  V Vindenes; H M E Lund; W Andresen; H Gjerde; S E Ikdahl; A S Christophersen; E L Øiestad
Journal:  Forensic Sci Int       Date:  2012-01-30       Impact factor: 2.395

2.  Confirmation by LC-MS of drugs in oral fluid obtained from roadside testing.

Authors:  Marta Concheiro; Ana de Castro; Oscar Quintela; Angelines Cruz; Manuel López-Rivadulla
Journal:  Forensic Sci Int       Date:  2007-07-20       Impact factor: 2.395

3.  DUID: oral fluid and blood confirmation compared in Belgium.

Authors:  Trudy Van der Linden; Sara-Ann Legrand; Peter Silverans; Alain G Verstraete
Journal:  J Anal Toxicol       Date:  2012-05-09       Impact factor: 3.367

4.  Evaluation of four oral fluid devices (DDS®, Drugtest 5000®, Drugwipe 5+® and RapidSTAT®) for on-site monitoring drugged driving in comparison with UHPLC-MS/MS analysis.

Authors:  Sabina Strano-Rossi; Erika Castrignanò; Luca Anzillotti; Giovanni Serpelloni; Roberto Mollica; Franco Tagliaro; Jennifer P Pascali; Delfina di Stefano; Roberto Sgalla; Marcello Chiarotti
Journal:  Forensic Sci Int       Date:  2012-05-01       Impact factor: 2.395

5.  Identification and quantitation of 11-nor-delta9-tetrahydrocannabivarin-9-carboxylic acid, a major metabolite of delta9-tetrahydrocannabivarin.

Authors:  M A ElSohly; S Feng; T P Murphy; A W Warrington; S Ross; A Nimrod; Z Mehmedic; N Fortner
Journal:  J Anal Toxicol       Date:  2001-09       Impact factor: 3.367

6.  Detection of cannabigerol and its presumptive metabolite in human urine after Cannabis consumption.

Authors:  E Hidvégi; G P Somogyi
Journal:  Pharmazie       Date:  2010-06       Impact factor: 1.267

7.  Nonsmoker Exposure to Secondhand Cannabis Smoke. III. Oral Fluid and Blood Drug Concentrations and Corresponding Subjective Effects.

Authors:  Edward J Cone; George E Bigelow; Evan S Herrmann; John M Mitchell; Charles LoDico; Ronald Flegel; Ryan Vandrey
Journal:  J Anal Toxicol       Date:  2015-07-02       Impact factor: 3.367

Review 8.  Cannabis effects on driving skills.

Authors:  Rebecca L Hartman; Marilyn A Huestis
Journal:  Clin Chem       Date:  2012-12-07       Impact factor: 8.327

9.  Detection of conjugated 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in oral fluid.

Authors:  Christine Moore; Sumandeep Rana; Cynthia Coulter; David Day; Michael Vincent; James Soares
Journal:  J Anal Toxicol       Date:  2007-05       Impact factor: 3.367

10.  Oral fluid cannabinoids in chronic frequent cannabis smokers during ad libitum cannabis smoking.

Authors:  Dayong Lee; Ryan Vandrey; Damodara R Mendu; Jeannie A Murray; Allan J Barnes; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2014-09-14       Impact factor: 3.345

View more
  20 in total

1.  Pharmacokinetics of Cannabis Brownies: A Controlled Examination of Δ9-Tetrahydrocannabinol and Metabolites in Blood and Oral Fluid of Healthy Adult Males and Females.

Authors:  Tory R Spindle; Edward J Cone; Evan S Herrmann; John M Mitchell; Ronald Flegel; Charles LoDico; George E Bigelow; Ryan Vandrey
Journal:  J Anal Toxicol       Date:  2020-10-12       Impact factor: 3.367

2.  Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes.

Authors:  Ryan Vandrey; Evan S Herrmann; John M Mitchell; George E Bigelow; Ronald Flegel; Charles LoDico; Edward J Cone
Journal:  J Anal Toxicol       Date:  2017-03-01       Impact factor: 3.367

3.  Free and Glucuronide Urine Cannabinoids after Controlled Smoked, Vaporized and Oral Cannabis Administration in Frequent and Occasional Cannabis Users.

Authors:  Marilyn A Huestis; Cristina Sempio; Matthew N Newmeyer; Maria Andersson; Allan J Barnes; Osama A Abulseoud; Benjamin C Blount; Jennifer Schroeder; Michael L Smith
Journal:  J Anal Toxicol       Date:  2020-10-12       Impact factor: 3.367

Review 4.  The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda.

Authors:  Mallory J E Loflin; Brian D Kiluk; Marilyn A Huestis; Will M Aklin; Alan J Budney; Kathleen M Carroll; Deepak Cyril D'Souza; Robert H Dworkin; Kevin M Gray; Deborah S Hasin; Dustin C Lee; Bernard Le Foll; Frances R Levin; Joshua A Lile; Barbara J Mason; Aimee L McRae-Clark; Ivan Montoya; Erica N Peters; Tatiana Ramey; Dennis C Turk; Ryan Vandrey; Roger D Weiss; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2020-04-26       Impact factor: 4.492

Review 5.  Aging circadian rhythms and cannabinoids.

Authors:  Erik L Hodges; Nicole M Ashpole
Journal:  Neurobiol Aging       Date:  2019-03-25       Impact factor: 4.673

6.  Acute Pharmacokinetic Profile of Smoked and Vaporized Cannabis in Human Blood and Oral Fluid.

Authors:  Tory R Spindle; Edward J Cone; Nicolas J Schlienz; John M Mitchell; George E Bigelow; Ronald Flegel; Eugene Hayes; Ryan Vandrey
Journal:  J Anal Toxicol       Date:  2019-05-01       Impact factor: 3.367

7.  Determination of Cannabinoid Vapor Pressures to Aid in Vapor Phase Detection of Intoxication.

Authors:  Tara M Lovestead; Thomas J Bruno
Journal:  Forensic Chem       Date:  2017-06-27

8.  Orally administered cannabidiol does not produce false-positive tests for Δ9 -tetrahydrocannabinol on the Securetec DrugWipe® 5S or Dräger DrugTest® 5000.

Authors:  Danielle McCartney; Richard C Kevin; Anastasia S Suraev; Christopher Irwin; Ronald R Grunstein; Camilla M Hoyos; Iain S McGregor
Journal:  Drug Test Anal       Date:  2021-08-30       Impact factor: 3.234

9.  Measuring Within-Individual Cannabis Reduction in Clinical Trials: A Review of the Methodological Challenges.

Authors:  Rachel L Tomko; Kevin M Gray; Marilyn A Huestis; Lindsay M Squeglia; Nathaniel L Baker; Erin A McClure
Journal:  Curr Addict Rep       Date:  2019-11-19

10.  Assessment of cognitive and psychomotor impairment, subjective effects, and blood THC concentrations following acute administration of oral and vaporized cannabis.

Authors:  Tory R Spindle; Erin L Martin; Megan Grabenauer; Thomas Woodward; Michael A Milburn; Ryan Vandrey
Journal:  J Psychopharmacol       Date:  2021-05-28       Impact factor: 4.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.